Key Highlights

  • Cycurion received a Nasdaq Staff Determination Letter on July 10, 2026 for trading below the $1.00 minimum bid price for 31 consecutive business days; it was denied the usual 180-day cure period and has an appeal hearing scheduled for August 2026.
  • Management publicly rejected a proposed 7-for-1 reverse split in a July 8, 2026 shareholder letter, arguing the mechanism would not fix the stock's volatility, citing its analysis of an October 2025 split.
  • Fiscal 2025 revenue was $15.1 million with a $23.7 million net loss driven by acquisition and stock-compensation charges; cash fell to $2.0 million at March 31, 2026, from $5.3 million at year-end 2025.
  • Cycurion's claims of "naked short selling" and "spoofing" are the Company's own assertions from its internal review; no regulator has publicly confirmed a formal investigation into the allegations.

Cycurion, Inc. (NASDAQ:CYCU) has told shareholders it will not pursue another reverse stock split, even as Nasdaq moves to delist the stock over a prolonged sub-$1.00 bid price. The cybersecurity contractor points to acquisitions and a widening government client base, alongside its own forensic review of trading it says shows manipulation, though no regulator has confirmed an investigation.

A Cybersecurity Contractor Fighting Two Battles at Once

Cycurion, Inc. (CYCU) is trying to convince shareholders that its stock-price problems reflect market structure, not the business. On July 8, 2026, Chairman and CEO Kevin Kelly published a letter announcing the Board had rejected a proposed 7-for-1 reverse split, arguing reverse splits "do not create value" and that a prior split failed to produce durable price support. Nine days later, Nasdaq delivered a rebuttal: a Staff Determination Letter dated July 10, 2026, notifying the Company its stock traded below the $1.00 minimum bid for 31 consecutive business days and, because Cycurion effected a 1-for-30 reverse split on October 27, 2025, it was ineligible for the standard 180-day grace period.

Absent an appeal, trading would have been suspended July 21, 2026. Cycurion requested a Hearings Panel review by the July 17 deadline, staying the suspension; a hearing is scheduled for August 2026, and CYCU continues trading on Nasdaq through that period.

Inside Cycurion's (CYCU) Cybersecurity and Public-Safety Platform

Based in McLean, Virginia, Cycurion describes itself as an AI-driven cybersecurity provider serving government, healthcare and corporate clients. Subsidiaries Axxum Technologies, Cloudburst Security and Cycurion Innovation sit under its ARx platform, combining geo-gate filtering, DDoS protection, web-application firewall and bot-detection tools. Cycurion has been acquisitive: it closed the Secuvant purchase, entered a May 2026 merger agreement for Halo Privacy and havenX, and in June 2026 signed an asset purchase agreement with Kustom Entertainment, Inc. (Nasdaq: KUST) for the Digital Ally-branded in-car video and body-worn camera business serving law enforcement. That deal closed in early July 2026, adding roughly 1,000 government customer relationships. Per the Company's July 8 letter, Digital Ally contributed about $5.1 million and Secuvant about $2.5 million toward revenue.

Catalyst Analysis: A Nasdaq Fight Layered on an Operational Pivot

For Cycurion, Inc., the Nasdaq listing fight and the market-abuse narrative are inseparable from the investment case. Management said its review found roughly 89.9 million CYCU shares changed hands in a single October 2025 session against a float of about 86.5 million shares, and that on March 16, 2026, the stock fell about 45% intraday, from near $1.75 to a low of $0.96, triggering the Regulation SHO Rule 201 circuit breaker. The Company said records from the following restricted-selling days showed a surge in "short exempt" sales and order patterns "consistent with additional acts of manipulation, including spoofing." Cycurion is pursuing a John Doe lawsuit, first announced in October 2025, to identify individuals it believes spread false information online.

These are Cycurion's own characterizations; no public confirmation from the SEC, FINRA or Nasdaq enforcement that a manipulation investigation has opened was found. Treat the claims as allegations, not adjudicated findings.

Latest Financial and Operational Performance

The Form 10-Q for the quarter ended March 31, 2026, filed May 14, 2026, showed revenue of $3.27 million, down from $3.87 million a year earlier, with a net loss attributable to Cycurion of $2.13 million, improved from a $10.25 million loss in the first quarter of 2025 tied to one-time business-combination expenses. For full-year 2025, per the 10-K filed March 31, 2026 (amended June 8, 2026), net revenue was $15.13 million, down from $17.77 million in 2024, with a net loss attributable to the Company of $23.67 million versus net income of $1.23 million in 2024, reflecting $11.87 million of business-combination expenses and $3.9 million of stock-based compensation tied to acquisitions.

Revenue, Cash Position, Debt and Recent Financing

As of March 31, 2026, Cycurion held $2.03 million in cash, down from $5.26 million at year-end 2025, after $12.1 million of operating cash use in 2025 largely offset by $6.98 million from a capital raise, $4.78 million from a private placement and $3.66 million from warrant exercises. Total liabilities were $17.76 million against total assets of $31.45 million, with interest-bearing obligations including a $2.73 million revolving credit line, $1.57 million of factoring liability, $2.5 million of promissory notes and roughly $1.5 million of other loans and convertible notes. Stockholders' equity was $13.68 million, and the Company filed several S-1 and 424B5 prospectuses in late 2025 and 2026 to support capital raises.

Growth Opportunities and Near-Term Milestones

Management's letter credits organic revenue growth to approximately $15.5 million and cites an annualized run rate "exceeding $28 million" once Digital Ally and Secuvant are included, along with a previously announced ten-year contract valued at approximately $58 million and roughly $8 million of contracted backlog. The near-term calendar centers on the August 2026 Nasdaq Hearings Panel, where Cycurion will present a compliance plan; a favorable ruling preserves the listing, while an adverse one pushes the stock over-the-counter. Integrating Digital Ally with ARx and completing the pending Halo Privacy and havenX deals are the other milestones to track.

Material Company-Specific Risks

The most immediate risk is binary: if the Hearings Panel denies continued listing or an extension, CYCU could move to over-the-counter markets, reducing liquidity. Having rejected a reverse split, management has fewer conventional tools left before the panel rules. Cycurion has posted a large net loss and a shrinking cash balance dependent on continued financing, and recent growth has come substantially from debt- and earnout-financed acquisitions still being integrated. The manipulation allegations remain unresolved by any regulator, and the John Doe litigation carries its own cost and uncertain timeline. Government-contract revenue is also exposed to the delayed federal spending the Company cited as a driver of 2025's weaker results.

Outlook

The upside case rests on the Hearings Panel accepting Cycurion's compliance plan, Digital Ally and Secuvant integrating cleanly toward the cited $28 million run rate, and backlog converting into revenue. The base case is a company managing integration costs and a listing appeal simultaneously, with lumpy results as acquisition charges roll off unevenly. The downside case involves an adverse panel decision, continued cash burn forcing dilutive financing, and manipulation claims that produce no regulatory remedy, leaving volatility unresolved. This article offers no price forecast; the August hearing and subsequent filings will determine the outcome.

Conclusion

Cycurion, Inc. (CYCU) has staked its credibility on convincing Nasdaq's Hearings Panel to preserve its listing without a fresh reverse split, and convincing shareholders that acquisitions and government contracts can outrun its cash burn. Both the delisting appeal and the market-abuse allegations remain unresolved; investors should watch the August 2026 hearing and subsequent SEC filings for clarity on Cycurion's direction.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.